Transplantation Therapeutics Research: Talks about leading products and key unmet needs within the market

This leads to an anti-graft immune response that involves T cells invading the new tissue, multiplying, and recruiting more immune cells to the transplant site in order to remove this foreign body.

Pune, India - March 14, 2018 /MarketersMedia/ —

In 2015 a total of 127,000 transplantations were performed worldwide, an increase of 5.8% from 2014, with 33,000 of these occurring in the EU and 32,000 in the US. Approximately 60% of these were kidney transplants, with liver, heart, lung, pancreas and small bowel transplantations accounting for the other most common procedures (Dominguez-Gil and Matesanz, 2017). When a graft is transplanted from a genetically non-identical individual, the recipient’s immune system recognizes the graft as foreign.
Access Report Details at: https://www.themarketreports.com/report/frontier-pharma-transplantation-therapeutics-a-highly-innovative-pipeline-with-a-range-of-adaptive-and-innate-immune-targeting-programs-focusing-on-graft-versus-host-disease-and-kidney-transplantation
Reasons To Buy
• Appreciate the current clinical and commercial landscapes by considering disease symptoms, pathogenesis, etiology, co-morbidities and complications, epidemiology, diagnosis, prognosis and treatment options for transplantation rejection.
• Identify leading products and key unmet needs within the market.
• Recognize trends in pipeline innovation by analyzing therapies by stage of development, molecule type and molecular target.
• Assess the therapeutic potential of first-in-class targets. Using a proprietary molecular target matrix assessment, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential.
• Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals, which may represent potential investment opportunities.
Get this report at: https://www.themarketreports.com/report/buy-now/935560
Scope
• There is a need for therapies that can achieve graft-specific immunosuppression, without having a general effect on the wider immune system. Which therapies and technologies currently in development are most likely to achieve this?
• There are 63 distinct first-in-class molecular targets in development for transplantation. Which of these hold the strongest potential in the clinic, and which are closest to reaching the market?
• How effective are current therapies for these indications, and how have they been able to improve the general prognosis in recent decades?
• Which molecule types and molecular targets are most prominent across transplantation therapy?
• Which specific types of transplantation are being most heavily studied across the pharmaceutical pipeline?
Inquire for more details at: https://www.themarketreports.com/report/ask-your-query/935560

Contact Info:
Name: Shirish Gupta
Email: [email protected]
Organization: The Market Reports
Address: SF-29, Sacred World, Wanawadi
Phone: 16314071315

Source URL: https://marketersmedia.com/transplantation-therapeutics-research-talks-about-leading-products-and-key-unmet-needs-within-the-market/314334

For more information, please visit https://www.themarketreports.com/report/frontier-pharma-transplantation-therapeutics-a-highly-innovative-pipeline-with-a-range-of-adaptive-and-innate-immune-targeting-programs-focusing-on-graft-versus-host-disease-and-kidney-transplantation%20%20

Source: MarketersMedia

Release ID: 314334